The interplay between thyroid and liver: implications for clinical practice
AbstractA complex relationship exists between thyroid and liver in health and disease. Liver plays an essential physiological role in thyroid hormone activation and inactivation, transport, and metabolism. Conversely, thyroid hormones affect activities of hepatocytes and hepatic metabolism. Serum liver enzyme abnormalities observed in hypothyroidism may be related to impaired lipid metabolism, hepatic steatosis or hypothyroidism-induced myopathy. Severe hypothyroidism may have biochemical and clinical features, such as hyperammonemia and ascites, mimicking those of liver failure. Liver function tests are frequently abnormal also in hyperthyroidism, due to oxidative stress, cholestasis, or enhanced osteoblastic activity. Antithyroid drug-associated hepatotoxicity is a rare event, likely related mainly to an idiosyncratic mechanism, ranging from a mild hepatocellular damage to liver failure. Propylthiouracil-induced liver damage is usually more severe than that caused by methimazole. On the other hand, thyroid abnormalities can be found in liver diseases, such as chronic hepatitis C, liver cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma. In particular, autoimmune thyroid diseases are frequently found in patients with hepatitis C virus infection. These patients, especially if thyroid autoimmunity preexists, are at risk of hypothyroidism or, less frequently, thyrotoxicosis, during and after treatment with interpheron-alpha alone or in combination with ribavirin, commo...
Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Jingrun Yang, Kuixia Xie, Chengxin Li
Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Na Fu, Huijuan Du, Dongdong Li, Yu Lu, Wencong Li, Yang Wang, Lingbo Kong, Jinghua Du, Suxian Zhao, Weiguang Ren, Fang Han, Rongqi Wang, Yuguo Zhang, Yuemin Nan
CONCLUSION: For better therapeutic outcome, proper selection of drug moiety with its appropriate administration is the major requisite. With the advent of nanotechnology, the development of nanocarrier for dermatologic application has been successfully demonstrated in positioning the systemically administrated drug into topical targeted delivery. In a nutshell, to achieve successful treatment strategies towards psoriasis, there is a need to focus on the development of stable, non-toxic nanocarrier for topical delivery. Inclusion of the existing orally administered drug moiety into nanocarriers for topical delivery is propo...
Publication date: Available online 4 June 2020Source: Cirugía Española (English Edition)Author(s): Clara Serrano Hermosilla, Mikel Prieto Calvo, Mikel Gastaca Mateo, Arkaitz Perfecto Valero, Andrés Valdivieso López
CONCLUSION: In HCC patients treated with TARE; macrovascular invasion, the activity of radiation dose, CPS, ECOG-PS, and infiltrative HCC predict OS and PFS. PMID: 32490691 [PubMed - as supplied by publisher]
In this study, we investigated the expressions of chemokines and their receptors during adipogenesis and inflammation in primary cultured orbital fibroblasts from patients with GO. METHODS: The messenger RNA (mRNA) expression levels of chemokines were compared between GO (n = 6) and non-GO (n = 5) orbital tissues by real-time polymerase chain reaction. After adipogenesis was induced in primary cultured orbital fibroblasts from patients with GO (n =5) and following stimulation with interleukin (IL)-1β and tumor necrosis factor (TNF)-α, the mRNA expression levels of chemokines and their receptors were analyzed...
Authors: Macruz CF, Lima SMRR, Postigo S, Martins MM, Lucarelli AP, de Oliveira VM Abstract OBJECTIVE: To assess quality of life and climacteric symptoms for post-menopausal women receiving hormone therapy for breast cancer. METHODS: A prospective observational study of women treated at the Mastology Outpatient Clinic of the Department of Obstetrics and Gynecology was conducted between 2015 and 2019. Post-menopausal patients who had been diagnosed with breast cancer and who were experiencing climacteric symptoms were selected. These patients had undergone surgery, radiotherapy, and/or chemotherapy more than one...
Conditions: COVID-19; Sars-CoV2; Cancer; Solid Tumor; Carcinoma; Blood Cancer Interventions: Drug: Part 1 - TL-895; Drug: Part 2 - TL-895; Drug: Part 2 - Placebo Sponsor: Telios Pharma, Inc. Not yet recruiting
Condition: Nasopharyngeal Carcinoma Intervention: Device: transoral flexible endoscope with magnifying narrow band imaging Sponsor: Chinese University of Hong Kong Not yet recruiting
Conditions: Carcinoma; Lung Cancer; NSCLC; Lung Neoplasms Intervention: Diagnostic Test: Breath test Sponsors: Peking University People's Hospital; Beijing Haidian Hospital; Aerospace 731 Hospital; Beijing Breatha Biological Technology Co., Ltd, Beijing Not yet recruiting
More News: Autoimmune Disease | Bile Duct Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Cholestasis | Cirrhosis | Endocrinology | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Hormones | Hyperthyroidism | Hypothyroidism | Liver | Liver Cancer | Liver Disease | Thyroid | Thyroid Cancer | Urology & Nephrology